Cellectis (CLLS) Liabilities and Shareholders Equity (2014 - 2026)

Cellectis' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $289.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 20.57% year-over-year to $289.2 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 15.46% YoY), while the FY2025 annual figure was $324.7 million, down 15.34% from the prior year.
• Liabilities and Shareholders Equity was $289.2 million for Q1 2026 at Cellectis, down from $324.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $407.1 million in Q2 2024 to a low of $209.7 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $320.5 million across 5 years, with a median of $334.3 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity tumbled 32.29% in 2022, then surged 88.78% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $261.2 million in 2022, then advanced by 27.97% to $334.3 million in 2023, then advanced by 14.74% to $383.5 million in 2024, then retreated by 15.34% to $324.7 million in 2025, then dropped by 10.94% to $289.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $289.2 million (Q1 2026), $324.7 million (Q4 2025), and $343.0 million (Q3 2025), per Business Quant data.